Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P

R H L Li1, J A Stern2, V Ho3

  • 1Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California Davis, Davis, CA. rhli@ucdavis.edu.

Insights

Clopidogrel effectively reduces platelet activation in most cats, though some individuals may not respond. Cats with the A31P mutation exhibit higher baseline platelet activation.

Area of Science:

  • Veterinary Pharmacology
  • Cardiovascular Research
  • Platelet Biology

Background:

  • Limited data exists on clopidogrel's antiplatelet effects in cats.
  • Thromboembolic events are a concern in feline cardiovascular disease.

Purpose of the Study:

  • To assess clopidogrel's impact on feline platelet responsiveness.
  • To investigate the influence of the MYBPC3 gene's A31P mutation on clopidogrel efficacy.
  • To characterize variability in cat platelet responses to clopidogrel.

Main Methods:

  • An ex vivo study involving 14 healthy cats (8 with A31P mutation, 6 wild-type).
  • Cats received clopidogrel (18.75 mg PO q24h) for 14 days.
  • Evaluated adenosine diphosphate (ADP)-induced P-selectin expression, platelet aggregation (optical aggregometry), pVASP, and ADP receptor response index (ARRI).

Main Results:

  • Clopidogrel attenuated ADP-induced P-selectin expression and platelet aggregation.
  • Cats with the A31P mutation showed significantly increased platelet activation compared to wild-type cats.
  • Significantly lower ARRI was observed post-clopidogrel treatment (P = .017).
  • Two of 13 cats were identified as non-responders.

Conclusions:

  • Clopidogrel is effective in reducing platelet activation and aggregation in a significant portion of cats.
  • The A31P mutation is associated with heightened platelet activation, contributing to variable responses.
  • Further research is needed to understand non-responder variability.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.4K